MAPT and tauopathy: In line with our analyses at an early-disease state when treatment was started (Fig. 4), the expression of the conventional anti-tau intrabody and the intrabody-K48R at a mid-disease stage were ineffective in eliminating or decreasing tauopathy in vivo in P301S-tg mice (Fig. 5a-b).